AGIO — AGIOS PHARMACEUTICALS, INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1439222 ·
Last close
$29.89
Market Cap
$1.79B
52W High
$46.00
52W Low
$22.24
ADV30
1,211,796
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 44,745,000 41,749,000 -110,552,000 -100,703,000 1,108,424,000 99,647,000 82,403,000
Mar 2026 20,746,000 19,427,000 -110,025,000 -99,111,000 1,184,990,000 113,600,000 75,875,000
Dec 2025 19,967,000 18,088,000 -121,578,000 -108,039,000 1,297,225,000 89,130,000 104,111,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-360,596,000
Investing CF
$367,153,000
Financing CF
$12,219,000
CapEx
$-29,656,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-6.25
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-761,519,000
Inventory
$30,152,000
Receivables
$24,216,000
ST Investments
$517,929,000
EBIT TTM
$-459,024,000
Pretax Income TTM
$-412,302,000
Interest Exp TTM
—
Analysts
8

Yahoo Snapshot (yfinance, live)

Total Revenue
$140,843,008
EBITDA
$-413,884,000
Free Cash Flow
$-264,320,880
Enterprise Value
$1,155,520,896
Total Cash
$630,009,024
Total Debt
$26,528,000
Shares Out
59,809,651
Trailing EPS
$-6.31
Book Value
$16.38
ROE
-32.9%
ROA
-21.4%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 54,028,000 -472,132,000 -412,781,000 1,297,225,000 104,111,000 1,193,114,000 -372,977,000
Dec 2024 36,498,000 -425,737,000 673,725,000 1,663,199,000 122,243,000 1,540,956,000 -389,841,000
Dec 2023 26,823,000 -391,487,000 -352,088,000 937,118,000 126,099,000 811,019,000 -296,062,000
Dec 2022 14,240,000 -389,047,000 -231,801,000 1,238,718,000 137,904,000 1,100,814,000 -309,478,000

TTM Snapshot

Revenues TTM
$98,338,000
NetIncome TTM
$-411,286,000
OpCashFlow TTM
—
Assets (Latest)
$1,108,424,000
Forward EPS
$-4.04

Max Pain — expiry 2026-12-18

max pain strike: $30.00 · spot: $29.68 · call oi: 30,446 · put oi: 1,658
Expected Move to 2026-12-18: ±$3.24 (10.92%) — implied range $26.44 – $32.92 · ATM straddle on $30.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ZYME Zymeworks Inc. $1.78B $25.84 —
TRAX First Tracks Biotherapeutics, Inc. $1.83B $43.57 —
ETON Eton Pharmaceuticals, Inc. $1.84B $63.65 —
STOK Stoke Therapeutics, Inc. $1.73B $26.41 —
HMDCF HUTCHMED (China) Ltd $1.88B $2.16 —

News headlines (Yahoo Finance, 1h cache)

Agios Pharmaceuticals (AGIO) Stock Looks Pricey Despite Its 39% Run
2026-11-07 09:10 · Yahoo
Agios Pharmaceuticals Inc (AGIO) (Q3 2026) Earnings Call Highlights: Revenue Surges 4x on ...
2026-11-06 23:08 · Yahoo
Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Beats Revenue Estimates
2026-11-05 12:15 · Yahoo
Agios Pharmaceuticals: Q3 Earnings Snapshot
2026-11-05 11:40 · Yahoo
Agios to Highlight Strength and Differentiation of Rare Hematology Portfolio with New Clinical Data for Mitapivat in Sickle Cell Disease and AG-236 in Polycythemia Vera at ASH 2026
2026-11-04 14:01 · Yahoo
Will FDA Review Delay Change Agios Stock Narrative
2026-11-04 08:18 · Yahoo
Agios Sinks 18% as FDA Delays Sickle Cell Drug Decision to 2027 Despite Being “Launch-Ready”
2026-10-30 15:56 · Yahoo
Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDA
2026-10-30 11:00 · Yahoo
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
2026-10-29 13:00 · Yahoo
Did Priority Review Just Shift Agios Pharmaceuticals' (AGIO) Investment Narrative?
2026-10-20 23:23 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.